` 600216 (Zhejiang Medicine Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

600216
vs
S
Shanghai Composite

Over the past 12 months, Zhejiang Medicine Co Ltd has underperformed Shanghai Composite, delivering a return of -15% compared to the Shanghai Composite's +13% growth.

Stocks Performance
600216 vs Shanghai Composite

Loading
600216
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
600216 vs Shanghai Composite

Loading
600216
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
600216 vs Shanghai Composite

Loading
600216
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Zhejiang Medicine Co Ltd vs Peers

Shanghai Composite
600216
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Zhejiang Medicine Co Ltd
Glance View

Market Cap
13B CNY
Industry
Pharmaceuticals

Zhejiang Medicine Co., Ltd., a stalwart in the pharmaceutical industry, traces its roots back to a time when China's economic landscape was rapidly transforming. Founded amidst the burgeoning wave of Chinese industrial expansion, the company made a calculated entry into the biopharmaceutical sector, a move that positioned it as an indispensable player in the realm of vitamins and antibiotics. Headquartered in the populous province of Zhejiang, the firm quickly honed its expertise in the manufacturing and export of fat-soluble vitamins, notably vitamin E, which became one of its hallmark products. Their robust production facilities and rigorous adherence to quality standards have not only fueled domestic demand but also secured a strong foothold in international markets, particularly Europe and the Americas. Zhejiang Medicine has crafted a diversified portfolio that spans active pharmaceutical ingredients (APIs) and advanced intermediates, offering a spectrum of products utilized by various health and pharmaceutical companies worldwide. A key revenue driver for the company lies in its vertical integration strategy, which enables it to maintain meticulous oversight over the entire production process, from raw materials to finished goods. The company’s commitment to R&D is evident in its investments in technology and innovation, allowing it to improve production efficiency and develop new compounds that cater to the evolving demands of the health sector. This approach not only insulates the company from market volatility but also fortifies its competitive position in a dynamic industry.

Intrinsic Value
24.81 CNY
Undervaluation 45%
Intrinsic Value
Price
Back to Top